Summary & Overview
CPT 81401: Molecular Pathology Procedure, Level 2
CPT code 81401 is a key billing code for Level 2 molecular pathology procedures, encompassing tests that analyze multiple genetic variants or detect dynamic mutation disorders. These laboratory services are essential for genetic screening, cancer diagnostics, and guiding personalized treatment strategies. Nationally, the code is recognized by major commercial payers including Aetna, Blue Cross Blue Shield, Cigna Health, and UnitedHealthcare, reflecting its widespread clinical and reimbursement relevance.
This publication provides a comprehensive overview of CPT 81401, detailing its clinical applications, typical laboratory settings, and payer coverage. Readers will gain insights into current policy updates, reimbursement benchmarks, and the evolving role of molecular pathology in precision medicine. The analysis also highlights common billing modifiers and associated taxonomies, offering clarity on coding practices and laboratory classifications. Additionally, relevant ICD-10 diagnoses and related CPT codes are discussed to contextualize the code within broader genetic testing and oncology workflows.
Healthcare professionals, laboratory administrators, and policy analysts will find actionable information on payer coverage, coding nuances, and clinical context for CPT 81401. The summary equips stakeholders with the knowledge needed to navigate the complexities of molecular pathology billing and policy trends.
CPT Code Overview
CPT 81401 represents a Level 2 molecular pathology procedure. This code is used for laboratory tests that analyze 2-10 single nucleotide polymorphisms (SNPs), one methylated variant, or one somatic variant, typically using nonsequencing target variant analysis. It also covers detection of dynamic mutation disorders or triplet repeat expansions. The service type is Molecular Pathology / Laboratory, and the typical site of service is an Independent Laboratory (POS 81). These procedures play a critical role in genetic testing, cancer diagnostics, and personalized medicine.
Clinical & Coding Specifications
Clinical Context
A patient is referred to an independent laboratory for molecular pathology testing to evaluate for specific genetic variants associated with cancer or hereditary disease. The laboratory receives a specimen (such as blood or tissue) and performs a Level 2 molecular pathology procedure, which may involve analyzing 2-10 single nucleotide polymorphisms (SNPs), detecting a single methylated variant, or identifying a somatic variant using nonsequencing target variant analysis. This testing is often ordered for patients with a personal or family history of cancer, uncertain neoplasm behavior, or for screening genetic and chromosomal anomalies. The workflow includes specimen collection, laboratory analysis, and reporting of results to the ordering provider for clinical decision-making.
Coding Specifications
-
Modifiers:
GX: Used when a notice of liability has been issued to the patient, voluntarily under payer policy. This modifier is typically applied when the laboratory believes the service may not be covered by the payor (such as Medicare) and has informed the patient.GY: Used when the item or service is statutorily excluded from coverage, does not meet the definition of any Medicare benefit, or is not a contract benefit for non-Medicare insurers.
-
Provider Taxonomies:
| Taxonomy Code | Specialty Name |
|---|---|
291U00000X | Clinical Medical Laboratory |
207ZP0102X | Pathology - Clinical Pathology/Laboratory Medicine |
207ZP0105X | Pathology - Molecular Genetic Pathology |
These taxonomies represent laboratories and pathologists specializing in clinical laboratory medicine and molecular genetic pathology.
Related Diagnoses
-
C80.1: Malignant (primary) neoplasm, unspecified- Used when a patient has a diagnosis of cancer but the primary site is not specified, relevant for molecular testing to identify somatic variants.
-
Z85.3: Personal history of malignant neoplasm of breast- Indicates a patient with a history of breast cancer, often prompting genetic testing for recurrence risk or hereditary cancer syndromes.
-
Z84.81: Family history of carrier of genetic disease- Used when there is a family history of genetic disease, supporting the need for molecular pathology testing to assess carrier status or risk.
-
Z13.79: Encounter for other screening for genetic and chromosomal anomalies- Applied when the patient is undergoing screening for genetic or chromosomal anomalies, which is a common indication for molecular pathology procedures.
-
D47.9: Neoplasm of uncertain behavior, unspecified- Used when a neoplasm's behavior is uncertain, supporting molecular testing to clarify diagnosis or guide management.
Related CPT Codes
81403: Molecular pathology procedure, Level 4 (eg, analysis of single exon by DNA sequence analysis, analysis of >10 amplicons using multiplex PCR in 2 or more independent reactions, mutation scanning or duplication/deletion variants of 2‑5 exons)
81403 is related to 81401 as both are molecular pathology procedures, but 81403 represents a higher complexity level. In clinical workflow, 81403 may be used when more extensive genetic analysis is required, such as sequencing a single exon or analyzing multiple amplicons. These codes may be used together if a patient requires both Level 2 and Level 4 testing, or as alternatives depending on the scope of genetic analysis ordered.
National Reimbursement Benchmarks
For CPT code 81401, the national mean rate for BUCA (average commercial) is $109.76, which is higher than the Aetna mean rate of $94.85 and lower than the Blue Cross Blue Shield mean rate of $124.04. Cigna and UnitedHealth Group also report mean rates above $100, at $115.56 and $107.51 respectively.
Rate dispersion, measured by the difference between the 75th and 25th percentiles, varies significantly across payers. Cigna shows the widest spread at $107.00, indicating substantial variability in reimbursement. Blue Cross Blue Shield and BUCA also have notable ranges of $66.00 and $64.59, respectively. Aetna and UnitedHealth Group display tighter ranges, with $56.80 and $63.00, suggesting more consistent rates among providers.
The table and chart below present the full breakdown of national benchmarks for CPT code 81401 across major commercial payers.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.